Urolog. pro Praxi, 2010; 11(3): 124-130

Current options of treatment of lower urinary tract symptoms

MUDr.Jiří Klečka, Ph.D., doc.MUDr.Milan Hora, Ph.D., MUDr.Petr Běhounek, MUDr.Viktor Eret, MUDr.Petr Stránský
Urologická klinika FN a LF UK v Plzni

The article review key trials of monotherapy and combination therapy of α1-adrenergic receptor antagonists (α1 ARA), 5α reduktase

inhibitors (5αIR) and antimuscarinic agents in the treatment of lower urinary tract symptoms (LUTS). We got an overview of role of different

medication possibilities and combination. In the treatment od LUTS including bladder outlet obstruction (BOO) with or without over

activ bladder (OAB) we can use four group of medicaion. Mentioned α1-adrenergic receptor antagonists and 5α reduktase inhibitors are

widela accepted in LUTS treatment. The new drugs used in BPH resp. OAB treatment are antimuscarinic agents and 5 phosphodiesterase

inhibitors or Botulotoxinum A.

antagonist, 5α reductase inhibitors, 5 phosphodiesterase inhibitors.

Keywords: LUTS (Lower Urinary Tract Symptom), OverActiv Bladder (OAB), Benign Prostate Hyperplasia (BPH), α1-adrenergic receptor

Published: June 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klečka J, Hora M, Běhounek P, Eret V, Stránský P. Current options of treatment of lower urinary tract symptoms. Urol. praxi. 2010;11(3):124-130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chapple CR, Sein AJ, Abrams P. Lower urinary tract symptoms revise: a broader clinical perspective. Eur Urol 2008; 54: 563-569. Go to original source... Go to PubMed...
    2. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ 1994; 308: 929-930. Go to original source... Go to PubMed...
    3. Abrams P, Blavais JG, Stanton SL. Standardization of terminology of lower urinary tract function. Neurourol Urodyn 1988; 7: 403-427. Go to original source...
    4. Abrams P, Cardovo L, Fall M. The standardization of terminology in lower urinary tract function: report from the Standardization Sub-committee on the International Continece Society. Am. J Obstet Gynecol 2002; 187: 116-126. Go to original source... Go to PubMed...
    5. Milsom I, Abrams P, Cardozo L. How widespread are the symptoms of an overactive bladder and how are they manager? A population - based prevalence study. BJU Int 2001; 87: 760-766. Go to original source... Go to PubMed...
    6. Stewart WF, Van Rooyen JB, Cundiff GW. Prevalence and burden of overactiv bladder in the United States. World J Urol 2003; 20: 327-336. Go to original source... Go to PubMed...
    7. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactiv bladder syndrome by applying the International Continece Society definition. Eur Urol 2005; 48: 622-627. Go to original source... Go to PubMed...
    8. Irwin D, Milsom I, Hunskaar S. Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: result of EPIC study. Eur Urol 2006; 50: 1306-1315. Go to original source... Go to PubMed...
    9. Turner-Warwick R, Whiteside CG, Worth PH, Milčou EJ, Bares CP. A urodynamic view of the clinical probléme associated with bladder - nech dysfunction and its treatment by endoscopic incision and trans - trigonal posterior prostatectomy. Br. J. Urol 1973; 45: 44-59. Go to original source... Go to PubMed...
    10. Norman RW, Nickel JC, Fish D, Pickett SN. Prostate related symptoms in Canadian men 50 years older: prevalence and relationship aminy symptoms. Br. J Urol 1994; 74: 542-550. Go to original source... Go to PubMed...
    11. Dallosso HM, Matthews RJ, McGrother CW. Leicestershire MRC Incintinence Study Group. The association of diet and other lifestyle factors with onset of overactiv bladder. A longitudinal study in men. Public Health Nutr 2004; 7: 885-891. Go to original source... Go to PubMed...
    12. de la Rosette J, Alivizatos G, Madersbacher S. European Association of Urology guidlines on benign prostatic hyperplasia. http://www.uroweb.org/fileadmin/txeuguidlines/BPH.pdf.
    13. Chapple CR. The total approach in lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) management. Introduction and conclusion. Eur Urol Suppl 2003; 2(7): 1-5. Go to original source...
    14. Farmer R, Hutchinson A, Chapple C. Comparison of the treatment regiment of new and existing LUTS/BPH patiens in 6 Europeans countries. Eur Urol Suppl 2004; 3(2): 60. Go to original source...
    15. Harkaway RC, Issa MM. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2006; 9: 204-214. Go to original source... Go to PubMed...
    16. Sung JC, Cuttis LH, Schulman KA, Albala DM. Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. J Urol 2006; 175: 1023-1027. Go to original source... Go to PubMed...
    17. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008; 28: 356-365. Go to original source... Go to PubMed...
    18. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsula and bladder neck. Brit J Urol 1975; 47: 193. Go to original source... Go to PubMed...
    19. Marshall I, Burt RP, Chapple R. Noradrenaline contractions of human prostate mediated by alpha 1A- (alpha 1c-) adrenoreceptor subtype. Br J Pharmacol 1995; 115: 781. Go to original source... Go to PubMed...
    20. Tamsulosin [package insert], Boehringer Ingelheim: Ridge-field, Conn, 2002.
    21. Van Moorselaar RJ, Hartung R, Emberton M, Harving N, Mazkin H, Elhilali M. Alfuzosin 10 mg once daily improves sexual function in man with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603-608. Go to original source... Go to PubMed...
    22. Elhilali MM, Ramsey EW, Barkin J, Casey RW, Boake RC, Beland G. A multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996; 47: 335-342. Go to original source... Go to PubMed...
    23. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 400-415. Go to original source... Go to PubMed...
    24. Roehrborn CG, for tha ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia; a randomized, placebo-controlled trial. Urology 2001; 58: 953-959. Go to original source... Go to PubMed...
    25. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900. Go to original source... Go to PubMed...
    26. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD. The effect of finasteride in men with benign prostatic hyperplasia. New Engl Med 1992; 327: 1185-1191. Go to original source... Go to PubMed...
    27. Marberger MJ, for the PROWESS Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. Urology 1998; 51: 677-686. Go to original source... Go to PubMed...
    28. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL. For the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-563. Go to original source... Go to PubMed...
    29. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-299. Go to original source... Go to PubMed...
    30. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405. Go to original source... Go to PubMed...
    31. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. far the ARIA3001, ARIA3002, and ARIA3003 Study Investigator. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441. Go to original source... Go to PubMed...
    32. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptom suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2006; 99: 85-96. Go to original source... Go to PubMed...
    33. Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A. Konservative management in neuropathic urinary incontinence. In: Abrahams P, Cardozo L, Kenzo S, Sein A. editors. Incontinence. Health publication 2002; 10: 697-754.
    34. O´Leary M, Ericsson JR, Smith CP, Mc Dermott C, Horton J, Chancellor MB. Effect of controlled - release oxybutinin bladder function in spinel cord injury. J SpinalCord Med 2003; 26: 159-162.
    35. Lethoranta K, Tainio H, Lukari-Lax E, Hakonen T, Tamela TN. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutinin in patiens with detrusor hyperaktivity. Scand J Urol Nephrol 20021; 36: 18-24. Go to original source... Go to PubMed...
    36. Radziszewski P, Borkowski A. Therapeutic effects of intrarectal administration of oxybutinin. Wiad Lek 2002; 55: 691-698. Go to PubMed...
    37. Madersbacher H, Murtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurologic and neurologic) World J Urol 2001; 19: 324-335. Go to original source... Go to PubMed...
    38. Frohlich G, Bulitta M, Strosser W. Trospium chloride in patiens with detrusor overactivity: meta-analysis of placebo controlled, randomized, double blind, multi-center clinical trials on the efficacy and safety of 20mg trospium chloride twice daily. Int J Clin Pharmacol Ther 2002; 40: 295-303. Go to original source...
    39. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25: 441-445. Go to original source... Go to PubMed...
    40. Kitisomprayoonkul W, Kovindha A. The efficacy of oxyphencyclimine hydrochloride in treatment of urinary incontinence in spinal cord injured patiens with detrusor sphincter dyssynergia. J Thai Rehabil 2000; 10: 23-26.
    41. Cardozo L, Lisec M, Miliard R, Van Vierssen Trip O, Kuzmin I, Drogendijk TE. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder, J Urol 2004; 172: 1919-1924. Go to original source... Go to PubMed...
    42. Anderson KE. Current concepts in treatment of disorders of micturition. Drugs 1988; 35: 477-494. Go to original source... Go to PubMed...
    43. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162: 3-11. Go to original source... Go to PubMed...
    44. Kim JH, Rival DA, Shenot PJ, Green B, Kennelly M, Ericsson JR, et al. Chancellor MB Intravesical resiniferatoxin for refractory detrusor hyperreflixia: a multicenter, blinded, radomizid, placebo-cotrolled trial. J spinal Cord Med 2003; 26: 359-363. Go to original source... Go to PubMed...
    45. de Seze M, Gallien P, Denys P, Labat JJ, Serment G, Grise P, et al. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study. Neurourol Urodyn 2006; 25: 752-757. Go to original source... Go to PubMed...
    46. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-650. Go to original source... Go to PubMed...
    47. Haferkapm A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004; 46: 784-791. Go to original source... Go to PubMed...
    48. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurologic detrusor overactivity. Eur Urol 2004; 45: 510-515. Go to original source... Go to PubMed...
    49. Kuo Hc. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003; 61: 550-554. Go to original source... Go to PubMed...
    50. de Seze M, Petit H, Gallien P, et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocainecontrolled study in 13 patients with spinal cord disease. Eur Urol 2002; 42: 56-62. Go to original source... Go to PubMed...
    51. Schurch B. Botulinum toxin for the management of bladder dysfunction. Drugs 2006; 66: 1301-1318. Go to original source... Go to PubMed...
    52. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssenergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71: 24-26.
    53. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurologic detrusor overactivity. Spinal Cord 2002; 40: 599-600. Go to original source... Go to PubMed...
    54. Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR, et al. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007; 69: 69-73. Go to original source... Go to PubMed...
    55. Galeo BJ, Galee MA. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Ann Pharmacother 2008; 42: 111-115. Go to original source... Go to PubMed...
    56. McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071-1077. Go to original source... Go to PubMed...
    57. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized placebo controlled study to assess the efficacy of twice daily Vardenafil in the treatment of LUTS secondary to BPH. Eur Urol 2008; 53: 1236-1244. Go to original source... Go to PubMed...
    58. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). www.auanet. org/guidelines/bph.cfm (updated 2006).
    59. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007; 29: 387-398. Go to original source... Go to PubMed...
    60. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-466. Go to original source... Go to PubMed...
    61. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, for the Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasterido, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-126. Go to original source... Go to PubMed...
    62. Roehrborn CG, Siami P, Barkin, Damiao R, Major Walkar K. Morrill B, for the Combination of Avodart and Tamsulosin (CombAT) Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-621. Go to original source... Go to PubMed...
    63. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008; 28: 356-365. Go to original source... Go to PubMed...
    64. Kaplan SA, Walmslay K, Te AE, Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-2276. Go to original source... Go to PubMed...
    65. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fistis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol 2003; 58: 2253-2256. Go to original source... Go to PubMed...
    66. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson N, Bavendam T, Guam Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-2328. Go to original source... Go to PubMed...
    67. Van Kerrenbroeck P, Kreder K, Jonas U, Zinner N, Wein A, for the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-421. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.